November 22, 2026
Zus Health Secures 33 Million Dollars in Series B Funding to Advance AI-Powered Unified Patient Records and Expand National Healthcare Data Networks

Zus Health Secures 33 Million Dollars in Series B Funding to Advance AI-Powered Unified Patient Records and Expand National Healthcare Data Networks

Zus Health, a pioneering healthcare technology platform focused on the seamless integration of clinical data, has officially announced the closing of a $33 million Series B funding round. This latest injection of capital is earmarked for the acceleration of the company’s mission to build a comprehensive, networked medical record that transcends the traditional silos of Electronic Health Record (EHR) systems. Led by Drive Capital, the financing round saw significant participation from a diverse syndicate of investors, including Sanofi Ventures, HealthX Ventures, Alumni Ventures, and existing backers Andreessen Horowitz (a16z), F-Prime, Maverick Ventures, and JAZZ Venture Partners. With this latest round, Zus Health has raised a total of more than $100 million since its inception, signaling robust investor confidence in the company’s ability to solve the long-standing problem of healthcare data fragmentation.

The funding comes at a critical juncture for the American healthcare system, which continues to grapple with the inefficiencies of disconnected digital records. Despite the widespread adoption of EHRs over the last two decades—accelerated by the HITECH Act of 2009—clinical information remains largely trapped within individual institutions or specific software ecosystems. Zus Health, founded by athenahealth co-founder Jonathan Bush, aims to move beyond these limitations by creating a platform that aggregates, cleans, and presents patient data from across the entire healthcare continuum, including pharmacies, laboratories, and competing EHR networks.

A Strategic Vision for Connected Healthcare

The core philosophy behind Zus Health is the belief that patient data should follow the patient, regardless of where care is delivered. Jonathan Bush, who serves as the CEO of Zus Health, has been a vocal critic of the "siloed" nature of modern medical records. In a statement following the funding announcement, Bush emphasized that the digital transformation of healthcare is incomplete as long as information remains static.

“The story of electronic medical records doesn’t end with the silos we have today,” Bush remarked. “We’ve spent decades digitizing healthcare, but the information still doesn’t move with the patient. We’re building a networked medical record that changes that—connecting information across the healthcare system and making it available to the people and applications that need it.”

The Series B capital will specifically support three primary pillars of the company’s growth strategy: the advancement of AI-powered clinical intelligence, the expansion of its national healthcare data network, and the development of specialized workflows tailored for value-based care and specialty medicine. By leveraging artificial intelligence, Zus Health intends to transform raw, unstructured data into actionable insights, allowing clinicians to spend less time hunting for information and more time engaging with patients.

The Role of AI in Clinical Intelligence

One of the most significant technological components of the Zus platform is its use of AI to generate concise patient summaries. In an era of "data overload," clinicians are often presented with hundreds of pages of medical history, much of it redundant or irrelevant to the current encounter. Zus Health’s AI algorithms scan unified records to highlight the most pertinent information, such as recent lab results, active medication lists, and historical diagnoses from outside providers.

The platform’s ability to generate "evidence citations" is a key differentiator in the market. Year-to-date, Zus has generated over 39 million evidence citations across its various solutions. These citations allow clinicians to see exactly where a piece of information originated—whether it was a discharge summary from a hospital across the state or a prescription fill record from a local pharmacy. This transparency is vital for building clinical trust in AI-generated summaries and ensuring that medical decisions are based on verifiable data.

Molly Bonakdarpour, a general partner at Drive Capital, highlighted the importance of this technological foundation. “We believe healthcare is entering a new era in which AI can fundamentally change how care is delivered, but that transformation depends on having reliable, connected patient information,” she stated. “Zus has built the foundation to address that challenge at scale. Its combination of technology, market opportunity, and leadership gives us conviction in the company’s ability to help shape the next generation of healthcare.”

Chronology of Growth and Market Traction

The journey of Zus Health reflects the broader evolution of the health-tech sector over the last five years. Founded in late 2020, Zus Health emerged with the goal of creating a "platform-as-a-service" for healthcare developers. The company recognized that while many digital health startups were building innovative care models, they were all struggling with the same fundamental hurdle: accessing and integrating patient data.

In 2021, Zus raised a $34 million Series A round led by Andreessen Horowitz, which allowed the company to build out its initial data pipelines. Since then, the company has rapidly scaled its infrastructure. By mid-2024, the platform had reached a massive scale, supporting more than 110 million networked transactions in the month of August alone. These transactions represent the exchange of patient records, medication histories, and clinical notes across the Zus network, providing a real-time look at the health of millions of Americans.

The company’s growth has been fueled by partnerships with forward-thinking healthcare organizations. Notable customers include Homeward Health, a technology-enabled healthcare provider focused on rural communities, and Circadian Health, a specialty care provider. These organizations use Zus to gain a 360-degree view of their patients, which is particularly critical in rural or specialized settings where patients often see multiple providers across different geographic regions.

Path Toward QHIN Status and TEFCA Integration

A pivotal part of Zus Health’s future roadmap is its commitment to the Trusted Exchange Framework and Common Agreement (TEFCA). In August 2026, Zus Health plans to formally pursue status as a Qualified Health Information Network (QHIN).

TEFCA is a federal initiative designed to create a "network of networks" for healthcare data exchange in the United States. By becoming a QHIN, Zus Health would join an elite group of organizations authorized to facilitate the secure exchange of health information on a national scale. This status would effectively place Zus at the center of the nation’s interoperability infrastructure, allowing its users to query and receive data from any other participating QHIN-connected entity in the country.

The move toward QHIN status is a logical progression for a company built on the principles of open data. It aligns with the Office of the National Coordinator for Health Information Technology (ONC) goals of reducing the technical and legal barriers that currently prevent the seamless flow of medical information. For Zus Health’s clients, this means even broader access to data and a future-proofed platform that complies with the highest federal standards for interoperability.

Impact on Value-Based Care and Specialty Medicine

The implications of the Zus Health platform are particularly profound for the shift toward value-based care (VBC). In a VBC model, providers are reimbursed based on patient outcomes rather than the volume of services rendered. To succeed in this model, providers must have a complete understanding of a patient’s health journey to prevent unnecessary hospitalizations, avoid duplicate testing, and manage chronic conditions effectively.

Fragmented data is one of the greatest risks to the financial viability of VBC organizations. If a patient is treated at an emergency room outside of the primary provider’s network, and that data is not shared, the primary provider cannot perform the necessary follow-up care to prevent a readmission. Zus Health’s unified record mitigates this risk by ensuring that every encounter across the healthcare system is captured and flagged for the care team.

In the realm of specialty care, Zus Health enables more precise interventions. For instance, a cardiologist using Zus can see not just the results of the tests they ordered, but also the medications prescribed by the patient’s primary care physician and the lifestyle data recorded by a digital health app. This level of integration is essential for managing complex diseases that require multi-disciplinary coordination.

Market Analysis and Competitive Landscape

The market for healthcare interoperability is increasingly crowded, with competitors ranging from legacy players like Epic (with its Care Everywhere network) to newer entrants like Health Gorilla and Particle Health. However, Zus Health distinguishes itself by moving beyond simple data transmission. While many "interoperability" companies focus on the "plumbing"—the movement of data from point A to point B—Zus focuses on the "refinery"—cleaning, deduplicating, and synthesizing that data into a usable clinical tool.

Furthermore, the involvement of Sanofi Ventures in this round suggests an increasing interest from the pharmaceutical industry in integrated health data. For life sciences companies, real-world data is becoming essential for clinical trial recruitment and monitoring the long-term efficacy of medications. A platform like Zus, which can track patient outcomes across various care settings, provides a high-fidelity data set that was previously difficult to assemble.

Conclusion: The Future of the Networked Medical Record

As Zus Health prepares for its next phase of growth, the focus remains on reducing the administrative and cognitive burden on healthcare providers. Jonathan Bush’s vision of a "borderless" medical record is closer to reality today than it was a decade ago, thanks to advancements in cloud computing, standardized APIs (such as FHIR), and now, generative AI.

The $33 million Series B funding provides Zus with the runway to solidify its position as a leader in the data intelligence space. By investing in AI and pursuing QHIN status, the company is positioning itself not just as a software provider, but as a fundamental utility for the modern healthcare system. If successful, Zus Health could represent the "connective tissue" that finally links the disparate parts of American medicine, leading to safer, more efficient, and more personalized care for patients across the country.

The upcoming years will be a test of the company’s ability to maintain its rapid transaction growth while navigating the complex regulatory landscape of TEFCA. However, with a veteran leadership team and the backing of some of the most influential venture capital firms in the world, Zus Health is well-equipped to lead the charge toward a truly interoperable healthcare future.

Leave a Reply

Your email address will not be published. Required fields are marked *